NCT07391761

A Real World Study of Elranatamab in Patients With RR Multiple Myeloma in Taiwan

A Multi-center Observational Study of the Effectiveness of Elranatamab in Patients With Relapsed and/or Refractory Multiple Myeloma in Taiwan

• Status: Not Yet Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 30 (estimated)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate: * What is the real-world effectiveness of elranatamab in patients with relapsed and/or refractory multiple myeloma (RRMM) in Taiwan? * What are the baseline and clinical characteristics of RRMM patients who have received eltanatamab in Taiwan? * What are the treatment patterns of RRMM patients receiving elranatamab in the real-world setting in Taiwan?

Detailed description

This study is seeking participants who: * have relapsed or refractory multiple myeloma (RRMM), * have received at least four prior lines of therapy (including a PI, an IMiD, and an anti-CD38 antibody), * are 18 years or older. Participants receive elranatamab according to the approved label in Taiwan and continue treatment until disease progression or discontinuation. The study will evaluate real-world effectiveness and describe patient characteristics and treatment patterns to better understand elranatamab use in routine care.

Conditions

• Refractory Multiple Myeloma (RRMM)

Interventions

Type	Name	Description
DRUG	Non intervention	Non intervention

Timeline

• Start date: 2026-03-31
• Primary completion: 2028-01-31
• Completion: 2028-01-31
• First posted: 2026-02-06
• Last updated: 2026-02-18

Locations

1 site across 1 country: Taiwan

Regulatory

• FDA-regulated drug study